ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry ANT-01 is in late-stage development as an adjunctive treatment for major...
The US Food and Drug Administration (FDA) has given clearance to ANeuroTech’s investigational new drug (IND) application, allowing the company to carry out a Phase IIIb trial of ANT-01 as an adjunctive anti-depression drug for major depressive disorder (MDD).
ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trialof adjunctive anti-depression drug, ANT-01 ANT-01 in development as an adjunctive treatment for Major Depressive Disorder...